Compare Ascendis Pharma A/S (ASND) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.85. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | JNK | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $98.19 |
52-Week Low | $163.32 | $94.66 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
JNK trades at $95.93, down 0.07% on the day, with a bearish technical signal from moving averages and oscillators showing neutral readings. The ETF has declared dividends for 2026, including $0.53 for H2-26. Recent news highlights strong bond ETF inflows amid inflation fears and potential Fed rate hikes, creating a volatile backdrop for high-yield bonds.
Outlook remains cautious due to bearish technicals and macroeconomic uncertainty. Opportunities exist for yield-seeking investors, but risks include interest rate sensitivity and fund fees. Investors should weigh the ETF's high-yield exposure against potential headwinds from rising rates and economic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
